Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 1, 1999, Pages 41-52

  Ogasawara, Takashi ^a   Itoh, Yoshinori ^a   Tamura, Masaru ^a   Mushiroi, Takeshi ^a   Ukai, Yojiro ^a   Kise, Masahiro ^a   Kimura, Kiyoshi ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

AF64A; Baclofen; Brain ischemia; ECS; NBM; NS 105; Passive avoidance response; Radial arm maze; Rat; Scopolamine

Indexed keywords

ANIRACETAM; BACLOFEN; BIFEMELANE; CHOLINE ACETYLTRANSFERASE; ETHYLCHOLINE MUSTARD AZIRIDINIUM; FASORACETAM; IDEBENONE; INDELOXAZINE; NOOTROPIC AGENT; PENTOBARBITAL; SCOPOLAMINE;

ACETYLCHOLINE RELEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INJURY; BRAIN ISCHEMIA; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CONVULSION; ELECTRIC SHOCK; GABAERGIC SYSTEM; MALE; MAZE TEST; MEMORY; NONHUMAN; ORAL DRUG ADMINISTRATION; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ANIMALS; AVOIDANCE LEARNING; BASAL GANGLIA; CEREBRAL CORTEX; COGNITION; ELECTROSHOCK; GAMMA-AMINOBUTYRIC ACID; MALE; MEMORY DISORDERS; MUSCARINIC ANTAGONISTS; NOOTROPIC AGENTS; PARASYMPATHETIC NERVOUS SYSTEM; PIPERIDINES; PROLINE; RATS; RATS, WISTAR; RECEPTORS, GABA-B; SCOPOLAMINE; SYNAPTOSOMES;

EID: 0032858817     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00108-2     Document Type: Article

References (50)

1. Ader R., Weijenen J.A.W.M., Moleman R. Relation of a passive avoidance response as a function of the intensity and duration of electric shock. Psychonom. Sci. 26:1972;125-128.
2. Alpern H.P., Marriott J.G. Short-term memory. Facilitation and disruption with cholinergic agents Physiol. Behav. 11:1973;571-575.
3. Altman H.J., Crosland R.D., Jenden D.J., Berman R.F. Further characterizations of the nature of the behavioral and neurochemical effects of lesions of the nucleus basalis of Meynert in the rat. Neurobiol. Aging. 6:1985;125-130.
4. B receptors and islet-activating protein, pertussis toxin, in bovine cerebral cortex. J. Biol. Chem. 260:1985;12653-12658.
5. Berman R.F., Crosland R.D., Jenden D.J., Altman H.J. Persisting behavioral and neurochemical deficits in rats following lesions of the basal forebrain. Pharmacol. Biochem. Behav. 29:1987;581-586.
6. Blitzer R.D., Wong T., Nouranifar R., Iyengar R., Landau E.M. Postsynaptic cAMP pathway gates early LTP in hippocampal CA1 region. Neuron. 15:1995;1403-1414.
7. Bowery N.G., Hill D.R., Hudson A.L., Doble A., Middlemiss D.N., Shaw J., Turnbull M. -)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature. 283:1980;92-94.
8. B receptor pharmacology. Annu. Rev. Pharmacol. 33:1993;109-139.
9. Castellano C., Brioni J.D., Nagahara A.H., McGaug J.L. Posttraining systemic and intra-amygdala administration of the gaba-b agonist baclofen impair retention. Behav. Neural Biol. 52:1989;170-179.
10. Cumin R., Bandle E.F., Gamzu E., Haefely W.E. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berlin). 78:1982;104-111.
11. Damsma G., Lammerts van Bueren D., Westerink B.H.C., Horn A.S. Determination of acetylcholine in the fentomole range by means of HPLC, a post-column enzyme reaction, and electrochemical detection. Chromatographia. 24:1987;827-831.
12. Dasheiff R.M., Savage D.D., McNamara J.O. Seizures down-regulate muscarinic cholinergic receptors in hippocampal formation. Brain Res. 235:1982;327-334.
13. Fisher A., Mantione C.R., Abraham D.J., Hanin I. Long term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo. J. Pharmacol. Exp. Ther. 222:1982;140-145.
14. Flicker C., Dean R.L., Watkins D.K., Fisher S.K., Bartus R.T. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacol. Biochem. Behav. 18:1983;973-981.
15. Frey V., Huang Y.-Y., Kandel E.R. Effects of cAMP stimulate a late stage of LTP in hippocampal CAl neurons. Science. 260:1993;1601-1664.
16. Friedman E., Lerer B., Kuster J. Loss of cholinergic neurons in the rat neocortex products deficits in passive avoidance learning. Pharmacol. Biochem. Behav. 19:1983;309-312.
17. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24:1975;407-409.
18. Giovannini M.G., Rodinó P., Mutolo D., Pepeu G. Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo. Drug Dev. Res. 28:1993;503-509.
19. Glick S.D., Zimmerberg B. Amnesic effects of scopolamine. Behav. Biol. 7:1972;245-254.
20. Gulati A., Nath C., Dhawan K.N., Bhargava K.P., Agarwal A.K., Seth P.K. Effect of electroconvulsive shock on central cholinergic (muscarinic) receptors. Brain Res. 240:1982;357-358.
21. Haga T., Noda H. Choline uptake systems of rat brain synaptosomes. Biochem. Biophys. Acta. 291:1973;564-575.
22. Hanin I. The AF64A model of cholinergic hypofunction. an update Life Sci. 58:1996;1955-1964.
23. Huang Y.-Y., Li X.-C., Kandel E.R. cAMP contributes to mossy fiber LTP by initiating both a covalently mediated early phase and macromolecular synthesis-dependent late phase. Neuron. 79:1994;69-79.
24. Isaacson J.S., Nicoll R.A. Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc. Natl. Acad. Sci. USA. 88:1991;10936-10940.
25. Itoh I., Tanabe S., Kohda A., Sugiyama H. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J. Physiol. 424:1990;533-544.
26. Itoh Y., Ogasawara T., Mushiroi T., Yamazaki A., Ukai Y., Kimura K. Effects of NS-3, a thyrotropin-releasing hormone analog, on in vivo acetylcholine release in rat brain. Regional differences and its sites of action. J. Pharmacol. Exp. Ther. 271:1994;884-890.
27. Kakihara M., Yamazaki N., Nagaoka A. Effects of idebenone (CV-2619) on the concentrations of acethylcholine and choline in various regions of rats with cerebral ischemia. Jpn. J. Pharmacol. 36:1984;357-363.
28. Kataoka K., Hayakawa T., Yuguchi T., Yamada K. Cholinergic deafferentation after focal cerebral infarct in rats. Stroke. 22:1991;1291-1296.
29. König, J. F. R.; Klippel, R. A.: The rat: A stereotaxic atlas of the forebrain and lower parts of the brain stem. Huntington, NY: R. E. Krieger Publishing; reprint 1970.
30. Lerer B., Stanley M., Demetriou S., Gershon S. Effect of electroconvulsive shock on muscarinic cholinergic receptors in rat cerebral cortex and hippocampus. J. Neurochem. 41:1983;1680-1683.
31. Leventer S.M., Mckeag D., Clancy M., Wulfert E., Hanin I. Intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) reduces release of acethylcholine from rat hippocampal slices. Neuropharmacology. 24:1985;453-459.
32. Leventer S.M., Wulfert E., Hanin I. Time course of ethylcholine aziridinium ion (AF64A)-induced cholinotoxicity in vivo. Neuropharmacology. 26:1987;361-365.
33. Liang K.C., Julen R.G., McGaugh J.L. Modulating effects of posttraining epinephrine on memory. Involvement of the amygdala noradrenergic system Brain Res. 368:1986;125-133.
34. Ogasawara T., Itoh Y., Tamura M., Ukai Y., Yoshikuni Y., Kimura K. NS-3, a TRH-analog, reverses memory disruption by stimulating cholinergic and noradrenergic systems. Pharmacol. Biochem. Behav. 53:1996;391-399.
35. Ogasawara T., Ukai Y., Tamura M., Kimura K. NS-3 (CG3703), an analog of thyrotropin-releasing hormone, ameliorates cognitive impairment in rats. Pharmacol. Biochem. Behav. 50:1995;499-503.
36. Oka M., Itoh Y., Shimizu T., Ukai Y., Yoshikuni Y., Kimura K. Involvement of metabotropic glutamate receptors in Gi- and Gs-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain. Brain Res. 754:1997;121-130.
37. Oka M., Itoh Y., Tatsuni S., Ma F.-H., Ukai Y., Yoshikuni Y., Kimura K. A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture. Naunyn Schmiedebergs Arch. Pharmacol. 356:1997;189-196.
38. Olton D.S., Walker J.A., Gage F.H. Hippocampal connections and spatial discrimination. Brain Res. 139:1978;295-308.
39. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1982;Academic Press, Sydney.
40. Pizzi M., Fallacara C., Arrighi V., Memo M., Spano P.-F. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J. Neurochem. 61:1993;683-689.
41. Pulsinelli W.A., Brierley J.B. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke. 10:1979;267-272.
42. Sandyk R., Gillman M.A. Baclofen-induced memory impairment. Clin. Neuropharmacol. 8:1985;294-295.
43. Schmidt-Kastner R., Paschen W., Ophoff B.S., Hossmann K.-A. A modified four-vessel occlusion model for induced incomplete forebrain ischemia in rats. Stroke. 20:1989;938-946.
44. B receptor up-regulation after repeated treatment Eur.J. Pharmacol. 338:1997;225-232.
45. Sitaram N. Cholinergic hypothesis of human memory. Review of basic and clinical studies Drug Dev. Res. 4:1984;481-488.
46. Swartzwelder H.S., Tilson H.A., McLamb R.L., Wilson W.A. Baclofen disrupts passive avoidance retention in rats. Psychopharmacology (Berlin). 92:1987;398-401.
47. Ukai, Y.; Nakagawa, Y.; Ishima, T.; Tamura, M.; Yamazaki, A.; Kimura, K.: A pyroglutaminamide derivative, LAM-105, improves learning and memory in rats by enhancing the cholinergic neuronal activity. 17th CINP Meet. Abstr. 362; 1990.
48. Weisskopf M.G., Castillo P.E., Zalutsky R.A. Mediation of hippocampal mossy fiber long-term potentiation by cyclic AMP. Science. 265:1994;1878-1882.
49. B receptors. J. Neurochem. 53:1989;753-758.
50. Wu Z.-L., Thomas S.A., Villacres E.C., Xia Z., Simmons M.L., Chavkin C., Palmiter R.D., Storm D.R. Altered behavior and long-term potentiation in type I adenylyl cyclase mutant mice. Proc. Natl. Acad. Sci. USA. 92:1995;220-224.